Autologous Dendritic Cell Vaccines for Non–Small-Cell Lung Cancer

Abstract

Vaccines were well tolerated and had biologic activity in a variety of NSCLC patients. Establishing an optimal approach will require comparative studies in well-defined NSCLC patient groups.